News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ATLAB Pharma and BZL Biologics Announce Exclusive Global Licensing Agreement for Lu-J591, a Novel Radiopharmaceutical in Phase IIB for the Treatment of Prostate Cancer


10/28/2011 9:50:02 AM

NANTES, France--(BUSINESS WIRE)--ATLAB Pharma SAS and BZL Biologics LLC have entered into a sublicense agreement to develop 177Lu-J591 for cancer treatment. It includes exclusive rights to manufacture, develop and commercialize this radiopharmaceutical product worldwide as well as a joint Phase IIB/III clinical validation program.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES